Sio Capital Management LLC Takes Position in Artivion, Inc. (NYSE:AORT)

Sio Capital Management LLC purchased a new position in shares of Artivion, Inc. (NYSE:AORT) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 121,178 shares of the company’s stock, valued at approximately $3,226,000. Artivion makes up approximately 1.3% of Sio Capital Management LLC’s holdings, making the stock its 20th largest holding. Sio Capital Management LLC owned about 0.29% of Artivion as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Perceptive Advisors LLC raised its stake in shares of Artivion by 4.7% in the second quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock valued at $71,658,000 after acquiring an additional 124,725 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Artivion by 1.3% during the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock worth $56,388,000 after purchasing an additional 33,982 shares during the last quarter. First Eagle Investment Management LLC increased its stake in shares of Artivion by 4.9% in the second quarter. First Eagle Investment Management LLC now owns 598,148 shares of the company’s stock valued at $15,342,000 after buying an additional 27,906 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Artivion by 58.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after buying an additional 125,668 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Artivion by 0.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 301,992 shares of the company’s stock worth $7,746,000 after acquiring an additional 2,018 shares during the last quarter. 86.37% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Oppenheimer raised their price target on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Needham & Company LLC restated a “buy” rating and set a $30.00 target price on shares of Artivion in a research report on Friday, September 27th. JMP Securities assumed coverage on Artivion in a research note on Wednesday, October 23rd. They issued an “outperform” rating and a $33.00 price target for the company. Finally, Stifel Nicolaus lifted their price objective on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, September 13th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $31.00.

Insider Buying and Selling at Artivion

In other Artivion news, CAO Amy Horton sold 12,430 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the transaction, the chief accounting officer now directly owns 139,989 shares in the company, valued at $3,664,912.02. This trade represents a 8.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 8.10% of the company’s stock.

Artivion Stock Up 1.4 %

Shares of AORT opened at $29.05 on Friday. The company has a 50 day moving average of $26.91 and a 200-day moving average of $25.75. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a twelve month low of $16.48 and a twelve month high of $30.00.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.